News

News

Sino Biopharm Was Named to Top 20 ESG Competitiveness List of China's Listed Pharmaceutical Enterprises in 2022

Release time:2022-11-04

On October 14, 2022, well-known pharmaceutical industry media E Pharmaceutical managers and China's leading independent corporate and society responsibility consulting agency BizDao Consulting jointly released the "ESG Competitiveness and ESG Investment Value List of Chinese pharmaceutical Listed Enterprises". With its excellent ESG management performance and outstanding industry competitiveness, Sino Biopharm has been selected into the "TOP20 ESG Competitiveness List of Listed Pharmaceutical Enterprises in China 2022".

 

 

This list is based on ESG reports and related ESG public information released by listed companies. It evaluates about 150 eligible A-share and H-share listed companies in China's pharmaceutical industry, analyzing the two dimensions of "ESG information transparency evaluation" and "ESG management performance evaluation". The "Top 20 ESG Competitiveness of Listed Pharmaceutical Enterprises in China 2022" list is selected to focus on the ESG performance of listed pharmaceutical enterprises in China, and emphasize the risk management and excess value of high-quality sustainable operations that ESG brings to enterprises.

 

This selection represents the industry and society's recognition of Sino Biopharm's comprehensive ESG competitiveness in the Chinese pharmaceutical industry, and means that ESG will become another new competitive field, winning more market recognition for the company. In the future, Sino Biopharm, as a leading innovative research and R&D-driven pharmaceutical group in China, will always uphold the value of "For the country, for the people and for the enterprise", support the strategy of Healthy China, seek health and well-being for more patients, treat more diseases, and also continue to commit to promote the harmonious development of the enterprise, employees, society and the environment. We will also continue to work to promote the harmonious development of the enterprise, employees, society and the environment, and create long-term value for ourselves and our partners from all walks of life.

Share: